Mariner LLC Sells 3,114 Shares of Evotec SE (NASDAQ:EVO)

Mariner LLC trimmed its holdings in Evotec SE (NASDAQ:EVO) by 22.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,500 shares of the company’s stock after selling 3,114 shares during the period. Mariner LLC’s holdings in Evotec were worth $44,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, DCF Advisers LLC increased its holdings in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock valued at $956,000 after acquiring an additional 12,816 shares during the last quarter. 5.81% of the stock is currently owned by institutional investors.

Evotec Stock Up 10.7 %

NASDAQ EVO opened at $4.33 on Friday. The stock has a 50 day moving average price of $3.61 and a 200-day moving average price of $4.16. Evotec SE has a one year low of $2.84 and a one year high of $5.68. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft upgraded Evotec from a “sell” rating to a “hold” rating in a research report on Thursday, April 24th.

Evotec Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.